• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Sciences >Faecal Calgranulin C Versus Faecal Calprotectin as Non Invasive Markers Distinguishing Functional From Organic Causes of Chronic Diarrhea
【24h】

Faecal Calgranulin C Versus Faecal Calprotectin as Non Invasive Markers Distinguishing Functional From Organic Causes of Chronic Diarrhea

机译：粪便钙粒蛋白C与粪便钙卫蛋白相对于区分慢性慢性腹泻的有机原因的功能的非侵入性标志物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The major challenge in inflammatory bowel disease is to achieve a sensitive and specific non invasive diagnostic marker. Recently, S100A12 (Calgranulin C) have been established to be elevated in the feces of patients with IBD. The objective was to investigate the utility of fecal S100A12, in comparison to fecal Calprotectin and standard inflammatory markers, as a screening and distinguishing marker for IBD and Irritable Bowel Syndrome (IBS) in patients with chronic diarrhea. Stool samples were obtained from 173 individuals presenting with gastrointestinal symptoms requiring endoscopy. Fecal S100A12, fecal Calprotectin and serum S100A12 levels were measured and correlated to final diagnosis and standard tests (ESR, CRP, platelet count, albumin, perinuclear anti-neutrophil and antineutrophil cytoplasmic antibodies. Full colonoscopy with histopathological examination was performed. Patients diagnosed with IBD had elevated fecal S100A12 (median 49.7 mg kg-1) and Calprotectin (median 385 mg kg-1) levels compared with the patients without IBD (n = 35, S100A12: Median 4.6 mg kg-1, p-1; p-1) for the detection of IBD were 93.91 and 97%, respectively whereas fecal Calprotectin (cutoff 35 mg kg-1) gave a sensitivity of 93.96% and a specificity of 84.2%. Both fecal markers were superior to the sensitivities and specificities of any standard inflammatory test. Both fecal S100A12 and Calprotectin are sensitive markers of gastrointestinal inflammation but fecal S100A12 provided exceptional specificity in distinguishing patients with IBD from patients without IBD.
机译：炎症性肠病的主要挑战是获得灵敏且特异的非侵入性诊断标记物。最近，已经确定S100A12（钙粒蛋白C）在IBD患者的粪便中升高。目的是研究与粪便钙卫蛋白和标准炎症标志物相比，粪便S100A12在慢性腹泻患者中作为IBD和肠易激综合征（IBS）的筛选和区分标志物的用途。粪便样本是从173名出现胃肠道症状需要内窥镜检查的个体中获得的。测量粪便S100A12，粪便钙卫蛋白和血清S100A12的水平，并将其与最终诊断和标准测试（ESR，CRP，血小板计数，白蛋白，核周抗中性粒细胞和抗中性粒细胞胞浆抗体）相关联，并进行全结肠镜检查并进行组织病理学检查。与没有IBD的患者相比，粪便S100A12（中值为49.7 mg kg -1 ）和钙卫蛋白（中值385 mg kg -1 ）水平升高（n = 35，S100A12：用于检测IBD的中位数4.6 mg kg -1 ，p-1 ; p-1 ）分别为93.91和97％，而粪便钙卫蛋白（截断值35 mg kg） -1 ）的敏感性为93.96％，特异性为84.2％，两种粪便标志物均优于任何标准炎症试验的敏感性和特异性，粪便S100A12和钙卫蛋白均是胃肠道炎症的敏感标志物但是粪便S100A12在区分患者方面提供了卓越的特异性没有IBD的患者患有IBD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号